{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:52:56Z","timestamp":1790387576540,"version":"4.1.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0235449","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T17:32:16Z","timestamp":1595871136000},"page":"e0235449","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-\u03b2, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab"],"prefix":"10.1371","volume":"15","author":[{"given":"C. L.","family":"Kemmerer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pernpeintner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ruschil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abdelhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Krumbholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1389-5539","authenticated-orcid":true,"given":"M. C.","family":"Kowarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"issue":"3","key":"pone.0235449.ref001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"SL Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0235449.ref002","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.4049\/jimmunol.1502448","article-title":"Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients","volume":"197","author":"N Claes","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"pone.0235449.ref003","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1212\/NXI.0000000000000309","article-title":"B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis","volume":"4","author":"A Schwarz","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"pone.0235449.ref004","article-title":"Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients","volume":"2","author":"J Habib","year":"2015","journal-title":"J Mult Scler"},{"issue":"4","key":"pone.0235449.ref005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jaut.2011.08.003","article-title":"B cells undergo unique compartmentalized redistribution in multiple sclerosis","volume":"37","author":"J Haas","year":"2011","journal-title":"J Autoimmun"},{"issue":"1\u20132","key":"pone.0235449.ref006","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2013.06.002","article-title":"The B1-cell subpopulation is diminished in patients with relapsing\u2013remitting multiple sclerosis","volume":"262","author":"C Torring","year":"2013","journal-title":"J Neuroimmunol"},{"issue":"Pt 7","key":"pone.0235449.ref007","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/brain\/awh486","article-title":"Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis","volume":"128","author":"S Cepok","year":"2005","journal-title":"Brain"},{"issue":"30","key":"pone.0235449.ref008","doi-asserted-by":"crossref","first-page":"11064","DOI":"10.1073\/pnas.0402455101","article-title":"Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis","volume":"101","author":"A Corcione","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"248","key":"pone.0235449.ref009","doi-asserted-by":"crossref","first-page":"248ra106","DOI":"10.1126\/scitranslmed.3008930","article-title":"Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis","volume":"6","author":"A Palanichamy","year":"2014","journal-title":"Sci Transl Med"},{"issue":"248","key":"pone.0235449.ref010","doi-asserted-by":"crossref","first-page":"248ra107","DOI":"10.1126\/scitranslmed.3008879","article-title":"B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes","volume":"6","author":"JNH Stern","year":"2014","journal-title":"Sci Transl Med"},{"issue":"2","key":"pone.0235449.ref011","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"AJ Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"2","key":"pone.0235449.ref012","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"CH Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"pone.0235449.ref013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1742-2094-9-93","article-title":"Cxcl13 is the major determinant for B cell recruitment to the CSF during neuroinflammation","volume":"9","author":"MC Kowarik","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"6","key":"pone.0235449.ref014","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/acn3.418","article-title":"Cns Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder","volume":"4","author":"MC Kowarik","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"pone.0235449.ref015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","article-title":"Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population","volume":"34","author":"G Boffa","year":"2020","journal-title":"CNS drugs"},{"issue":"3","key":"pone.0235449.ref016","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1212\/WNL.51.3.682","article-title":"Interferon beta in the treatment of multiple sclerosis: Mechanisms of action","volume":"51","author":"VW Yong","year":"1998","journal-title":"Neurology"},{"key":"pone.0235449.ref017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaut.2014.05.005","article-title":"Immunomodulation neuroprotection and remyelination\u2014the fundamental therapeutic effects of glatiramer acetate: A critical review","volume":"54","author":"R Aharoni","year":"2014","journal-title":"J Autoimmun"},{"issue":"2","key":"pone.0235449.ref018","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4049\/jimmunol.1601649","article-title":"Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis","volume":"198","author":"R Li","year":"2017","journal-title":"J Immunol"},{"issue":"11","key":"pone.0235449.ref019","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-016-0603-2","article-title":"Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation","volume":"76","author":"H-C Tsai","year":"2016","journal-title":"Drugs"},{"issue":"9","key":"pone.0235449.ref020","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3174\/ajnr.A2226","article-title":"Natalizumab (Tysabri)","volume":"31","author":"DT Selewski","year":"2010","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6364","key":"pone.0235449.ref021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against \u03b1 4 \u03b2 l integrin","volume":"356","author":"TA Yednock","year":"1992","journal-title":"Nature"},{"issue":"8","key":"pone.0235449.ref022","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/1352458518775550","article-title":"Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients","volume":"24","author":"EA Mills","year":"2018","journal-title":"Mult Scler"},{"issue":"3","key":"pone.0235449.ref023","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/eji.201142108","article-title":"Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis","volume":"42","author":"R Planas","year":"2012","journal-title":"Eur J Immunol"},{"issue":"5580","key":"pone.0235449.ref024","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.1071632","article-title":"Integrin-mediated long-term B cell retention in the splenic marginal zone","volume":"297","author":"TT Lu","year":"2002","journal-title":"Science"},{"issue":"1","key":"pone.0235449.ref025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"DH Miller","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0235449.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-019-1593-2","article-title":"Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients","volume":"16","author":"JW Traub","year":"2019","journal-title":"Journal of neuroinflammation"},{"issue":"1","key":"pone.0235449.ref027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-011-0104-6","article-title":"Targeting leukocyte migration and adhesion in Crohn\u2019s disease and ulcerative colitis","volume":"20","author":"S Thomas","year":"2012","journal-title":"Inflammopharmacology"},{"issue":"15","key":"pone.0235449.ref028","doi-asserted-by":"crossref","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice","volume":"92","author":"D Mehta","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"pone.0235449.ref029","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1038\/s41598-018-26519-w","article-title":"Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients","volume":"8","author":"GM Diaz","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"pone.0235449.ref030","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1177\/1352458514523496","article-title":"Differential effects of fingolimod on B-cell populations in multiple sclerosis","volume":"20","author":"M Nakamura","year":"2014","journal-title":"Mult Scler"},{"issue":"11","key":"pone.0235449.ref031","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jamaneurol.2014.1472","article-title":"The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis","volume":"71","author":"SJ Ireland","year":"2014","journal-title":"JAMA Neurol"},{"issue":"11","key":"pone.0235449.ref032","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40263-018-0567-8","article-title":"Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis","volume":"32","author":"S Kuerten","year":"2018","journal-title":"CNS Drugs"},{"issue":"9","key":"pone.0235449.ref033","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/icb.2016.55","article-title":"Interferon-\u03b2 therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis","volume":"94","author":"F Rizzo","year":"2016","journal-title":"Immunol Cell Biol"},{"issue":"5","key":"pone.0235449.ref034","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"B Ceronie","year":"2018","journal-title":"J Neurol"},{"issue":"1","key":"pone.0235449.ref035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","article-title":"B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis","volume":"30","author":"SA Thompson","year":"2010","journal-title":"Journal of clinical immunology"},{"key":"pone.0235449.ref036","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis","volume":"16","author":"D Baker","year":"2017","journal-title":"EBioMedicine"},{"issue":"4","key":"pone.0235449.ref037","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"L Kappos","year":"2014","journal-title":"Lancet Neurol"},{"issue":"10","key":"pone.0235449.ref038","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1002\/eji.201040516","article-title":"Memory B cells from a subset of treatment-na\u00efve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-\u00df-\u03b3 production in response to myelin basic protein and myelin oligodendrocyte glycoprotein","volume":"40","author":"CT Harp","year":"2010","journal-title":"Eur J Immunol"},{"issue":"1","key":"pone.0235449.ref039","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis","volume":"175","author":"I Jelcic","year":"2018","journal-title":"Cell"},{"issue":"14","key":"pone.0235449.ref040","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","article-title":"Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS","volume":"76","author":"MC Kowarik","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"pone.0235449.ref041","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"O St\u00fcve","year":"2006","journal-title":"Ann Neurol"},{"issue":"17","key":"pone.0235449.ref042","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","article-title":"Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis","volume":"71","author":"M Krumbholz","year":"2008","journal-title":"Neurology"},{"issue":"10","key":"pone.0235449.ref043","doi-asserted-by":"crossref","first-page":"e111115","DOI":"10.1371\/journal.pone.0111115","article-title":"Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study","volume":"9","author":"N Claes","year":"2014","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0235449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T17:32:59Z","timestamp":1595871179000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0235449"}},"subtitle":[],"editor":[{"given":"Yolande","family":"Richard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0235449","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]}}}